What one share of CG Oncology holds
We are a late-stage clinical biopharmaceutical company focused on developing and commercializing cretostimogene grenadenorepvec (cretostimogene), an investigational oncolytic immunotherapy with a dual mechanism of action designed both to eliminate cancer cells directly by selective replication and indirectly by activating an anti-tumor immune response, as a potential backbone therapy in a broad range of patients afflicted with bladder cancer.
CG Oncology’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.08 |
|---|---|
| Profit | −$2.73 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$2.18 |
| Cash and investments | $11.64 |
| Debt | $0.03 |
| Book value | $11.65 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | $0.05 | −$15.65 | — | — | — | −$23.57 |
| 2024 | $0.02 | −$1.41 | $0.00 | −$1.26 | — | $9.63 |
| 2025 | $0.05 | −$2.08 | $0.00 | −$1.71 | — | $9.33 |
Common questions about CG Oncology
How much does one share of CG Oncology earn?
Over the last 12 months, CG Oncology lost $2.73 for each share on $0.08 of sales.
Does CG Oncology pay a dividend?
CG Oncology didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is CG Oncology’s book value per share?
CG Oncology’s book value is $11.65 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of CG Oncology have?
Each share of CG Oncology has $11.64 of cash and investments and $0.03 of debt, as of June 30, 2026.
What is CG Oncology’s free cash flow per share?
−$2.18 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.